Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013

Zhang, A; Huang, Yang; Tian, Di; Lau, Eric H. Y.; Wan, Yao; Liu, Xiaoyu; Dong, Yuan; Song, Zhigang; X, Zhang; Zhang, Jingwan; Bao, Ming; Zhou, Minghao; Yuan, Songhua; Sun, Jun; Zhang, Zhu; Hu, Yifei; Chen, L; Leung, Connie Y. H.; Jt, Wu; Zhang, Z; Peiris, Malik; Xu, Jianguo

doi:10.2807/1560-7917.es2013.18.50.20657

Cited by 30 publications

(27 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the timing of neutralizing antibody titer rise during illness mirrored the rise in HAI antibody titers; however, compared with a study of neutralizing antibodies in serial blood specimens from patients infected with influenza A(H7N9) virus, there was a more rapid rise in neutralizing antibodies to influenza A(H1N1)pdm09 virus infection in our cohort [8]. This difference may be due to immunological priming due to pre-pandemic exposure to influenza A(H1N1) viruses among subjects included in this study.…”

Section: Discussionmentioning

confidence: 61%

“…Most studies investigating the antibody response during influenza virus infection have focused on 2 time points of sera collection relative to symptom onset, but more specimen collection time points are needed to fully understand the kinetics of the antibody response during severe influenza and the impact of antibody titers on outcomes of infection. The few studies that have assessed antibodies from serial blood specimen collections suggest that low antibody titers early after influenza virus infection and slow increases in titers are predictive of death from fulminant illness [7, 8]. However, these studies are limited by their small sample size and unique clinical setting.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011

Rolfes

Gross

Flannery

et al. 2018

The Journal of Infectious Diseases

View full text Add to dashboard Cite

Background The kinetics of the antibody response during severe influenza are not well documented. Methods Critically ill patients infected with 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09), confirmed by reverse-transcription polymerase chain reaction analysis or seroconversion (defined as a ≥4-fold rise in titers), during 2009–2011 in Canada were prospectively studied. Antibody titers in serially collected sera were determined using hemagglutinin inhibition (HAI) and microneutralization assays. Average antibody curves were estimated using linear mixed-effects models and compared by patient outcome, age, and corticosteroid treatment. Results Of 47 patients with A(H1N1)pdm09 virus infection (median age, 47 years), 59% had baseline HAI titers of <40, and 68% had baseline neutralizing titers of <40. Antibody titers rose quickly after symptom onset, and, by day 14, 83% of patients had HAI titers of ≥40, and 80% had neutralizing titers ≥40. Baseline HAI titers were significantly higher in patients who died compared with patients who survived; however, the antibody kinetics were similar by patient outcome and corticosteroid treatment. Geometric mean titers over time in older patients were lower than those in younger patients. Conclusions Critically ill patients with influenza A(H1N1)pdm09 virus infection had strong HAI and neutralizing antibody responses during their illness. Antibody kinetics differed by age but were not associated with patient outcome.

show abstract

Section: Discussionmentioning

confidence: 61%

mentioning

confidence: 99%

Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011

Rolfes

Gross

Flannery

et al. 2018

The Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Of the 4 subjects hospitalized with influenza B, 2 were infected with viruses from the Yamagata lineage, 1 was infected with a virus from the Victoria lineage, and 1 virus could not be sequenced (Supplemental Table 1 HI and FRA. HI and luciferase-based pseudovirus neutralization (with an HIV backbone carrying H7 and N9) assays with H7N9-infected sera were performed as previously described (6,7). HI assays with plasma/sera from subjects with seasonal influenza infections were carried out as described in Kristensen et al (35).…”

Section: Methodsmentioning

confidence: 99%

“…Neutralizing antibodies (Abs) (NAbs), T cells, and natural killer (NK) cell responses were associated with recovery in a cohort of 18 subjects with severe human H7N9 infection (6,7). In the absence of vaccination, partial immunity to seasonal influenza is driven by immune responses to repeated infections with related strains.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fc functional antibodies in humans with severe H7N9 and seasonal influenza

Vanderven¹,

Liu²,

Ana-Sosa-Batiz³

et al. 2017

JCI Insight

View full text Add to dashboard Cite

Characterization of antibody and memory T-cell response in H7N9 survivors: a cross-sectional analysis

Wang

et al. 2020

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Objectives: Despite the importance of immunological memory for protective immunity against viral infection, whether H7N9-specific antibodies and memory T-cell responses remain detectable years after the original infection is unknown. Methods: A cross-sectional study was conducted to investigate the immune memory responses of H7N9 patients who contracted the disease and survived during the 2013e2016 epidemics in China. Sustainability of antibodies and T-cell memory to H7N9 virus were examined. Healthy individuals receiving routine medical examinations in a physical examination centre were recruited as control. Results: A total of 75 survivors were enrolled and classified into four groups based on the time elapsed from illness onset to specimen collection: 3 months (n ¼ 14), 14 months (n ¼ 14), 26 months (n ¼ 28) and 36 months (n ¼ 19). Approximately 36 months after infection, the geometric mean titres of virus-specific antibodies were significantly lower than titres in patients 3 months after infection, but 16 of 19 (84.2%) survivors in the 36-month interval had microneutralization (MN) titres !40. Despite the overall declining trend, the percentages of virus-specific cytokine-secreting memory CD4 þ and CD8 þ T cells remained higher in survivors at nearly all time-points in comparison with control individuals. Linear regression analysis showed that severe disease (mean titre ratio 2.77, 95% CI 1.17e6.49) was associated with higher haemagglutination inhibition (HI) titre and female sex for both HI (1.92, 1.02e3.57) and MN (3.33, 1.26e9.09) antibody, whereas female sex (mean percentage ratio 1.69, 95% CI 1.08e2.63), underlying medical conditions (1.94, 95% CI 1.09e3.46) and lack of antiviral therapy (2.08, 95% CI 1.04e4.17) were predictors for higher T-cell responses. Conclusions: Survivors of H7N9 virus infection produced long-term antibodies and memory T-cell responses. Our findings warrant further serological investigation in general and high-risk populations and have important implications for vaccine design and development.

show abstract

Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013

Abstract: Binary file ES_Abstracts_Final_ECDC.txt matches

Cited by 30 publications

References 16 publications

Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011

Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011

Fc functional antibodies in humans with severe H7N9 and seasonal influenza

Characterization of antibody and memory T-cell response in H7N9 survivors: a cross-sectional analysis

Contact Info

Product

Resources

About